Dossier
MOTS-c
Coverage of MOTS-c in the Nexus archive.
- FDA panel overrules its own scientists to ease access to unproven peptide injections
The FDA's Pharmacy Compounding Advisory Committee voted 8-6 to recommend four unproven peptides (BPC-157, KPV, TB-500, and MOTS-c) for access through compounding pharmacies, despite scientific concerns.
- FDA panel votes to add peptides to permitted compounding list despite opposition from agency scientists
The FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted to add peptides like BPC-157, KPV, TB-500, and MOTS-c to the list of substances compounding pharmacies can make, despite opposition from FDA scientists over concerns about their unproven benefits.